Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 9:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 67 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pulmonary Embolism (PE) Clear all
Suspended No phase listed Observational

Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE

NCT06310018
View directory record Official record
Conditions
Pulmonary Embolism, Right Ventricular Dysfunction, Right Ventricular Failure
Interventions
Ultrasound-facilitated, catheter-directed lower-dose fibrinolysis, Tissue Plasminogen Activator
Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 1, 2026, 9:19 PM EDT
Completed Phase 3 Interventional Results available

Cancer Venous Thromboembolism (VTE)

NCT02073682
View directory record Official record
Conditions
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cancer
Interventions
Edoxaban, Dalteparin, Low molecular weight heparin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,046 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Brandon, Florida • Jonesboro, Georgia • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 1, 2026, 9:19 PM EDT
Completed Not applicable Interventional Results available

Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)

NCT00358735
View directory record Official record
Conditions
Deep Vein Thrombosis of Lower Limb, Pulmonary Embolism (PE), Bleeding
Interventions
ActiveCare CECT device, Enoxaparin
Device · Drug
Lead sponsor
Medical Compression Systems
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
La Jolla, California • Loma Linda, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Sep 1, 2026, 9:19 PM EDT
Completed No phase listed Observational

Multi-Center Human Alert Trial to Prevent DVT and PE

NCT00409136
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis, Cancer, Surgery
Interventions
Human Alert
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2,496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
26
States / cities
Scottsdale, Arizona • Long Beach, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2009 · Synced Sep 1, 2026, 9:19 PM EDT
Not yet recruiting Phase 4 Interventional

Extended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease

NCT07713875
View directory record Official record
Conditions
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Spine Metastasis
Interventions
Apixaban
Drug
Lead sponsor
James Bayley
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Pittburgh, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 1, 2026, 9:19 PM EDT
Completed Phase 3 Interventional Results available

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study

NCT00439777
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin overlapping with and followed by VKA
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
4,833 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
23
States / cities
Little Rock, Arkansas • Redlands, California • Bay Pines, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2014 · Synced Sep 1, 2026, 9:19 PM EDT
Suspended Not applicable Interventional

CLEANer Aspiration for Pulmonary Embolism

NCT06189313
View directory record Official record
Conditions
Pulmonary Embolism, Acute Pulmonary Embolism, Cardiovascular Diseases, Venous Thromboembolism
Interventions
Cleaner Pro Thrombectomy System
Device
Lead sponsor
Argon Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 1, 2026, 9:19 PM EDT
Completed Not applicable Interventional Results available

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

NCT02744092
View directory record Official record
Conditions
Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Blood Clot
Interventions
Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Warfarin, Dalteparin, Enoxaparin, Fondaparinux
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
151
States / cities
Chula Vista, California • Fremont, California • Fresno, California + 104 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Sep 1, 2026, 9:19 PM EDT
Completed No phase listed Observational

Risk Factors for Venous Thromboembolism in the Community

NCT00011180
View directory record Official record
Conditions
Cardiovascular Diseases, Thromboembolism
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Sep 1, 2026, 9:19 PM EDT
Suspended Not applicable Interventional

Safety and Effectiveness of the Akura Thrombectomy System for Use in the Removal of Emboli From the Pulmonary Arteries in Treating Acute Pulmonary Embolism (PE)

NCT06672510
View directory record Official record
Conditions
Pulmonary Embolism Acute
Interventions
ATC
Device
Lead sponsor
Akura Medical
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Thousand Oaks, California • Hartford, Connecticut • Bradenton, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 1, 2026, 9:19 PM EDT
Completed No phase listed Observational

Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data

NCT04879407
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Rivaroxaban, Warfarin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
98,947 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 1, 2026, 9:19 PM EDT
Completed No phase listed Observational Results available

RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism

NCT02596230
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
7,797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
19
States / cities
Long Beach, California • Miami, Florida • Pembroke Pines, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Sep 1, 2026, 9:19 PM EDT
Recruiting Not applicable Interventional

The RAPID - PE Study: RESCUE Advanced Protocol for the Treatment of Pulmonary Embolism

NCT06433011
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
The Bashir™ Endovascular Catheter, r-tPA
Device · Drug
Lead sponsor
Thrombolex, Inc.
Industry
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Scottsdale, Arizona • Tuscon, Arizona • Lakeland, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 1, 2026, 9:19 PM EDT
Withdrawn No phase listed Observational

Arixtra PE Study- Outpatient Management of Stable Acute Pulmonary Embolism: Once Daily Subcutaneous Fondaparinux

NCT00378027
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Fondaparinux
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Sep 1, 2026, 9:19 PM EDT
Completed Early Phase 1 Interventional

Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in Bariatric Surgical Patients

NCT00894283
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Enoxaparin, Fondaparinux
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Sep 1, 2026, 9:19 PM EDT
Completed Phase 3 Interventional Results available

Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy

NCT01513759
View directory record Official record
Conditions
Pulmonary Embolism, Acute Pulmonary Embolism, Sub-massive Pulmonary Embolism, Massive Pulmonary Embolism, Pulmonary Thromboembolism
Interventions
recombinant tissue plasminogen activator, EKOS EkoSonic Endovascular System
Drug · Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
22
States / cities
Montgomery, Alabama • Modesto, California • Stanford, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2021 · Synced Sep 1, 2026, 9:19 PM EDT
Completed Phase 3 Interventional Results available

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.

NCT00362232
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Placebo: tablet of Rivaroxaban, Placebo: syringes of Enoxaparin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
3,148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
40
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Sep 1, 2026, 9:19 PM EDT
Completed Not applicable Interventional Results available

A Prospective, Multi-Center Study of the Bard® Denali™ Retrievable Inferior Vena Cava Filter System

NCT01305564
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Denali inferior vena cava filter
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hartford, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Sep 1, 2026, 9:19 PM EDT
Withdrawn Phase 3 Interventional

Macitentan to Prevent PRVO

NCT05946811
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Macitentan 10mg
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Sep 1, 2026, 9:19 PM EDT
Completed Phase 3 Interventional Results available

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients

NCT00571649
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Rivaroxaban placebo, Enoxaparin placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older
Enrollment
8,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
121
States / cities
Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Sep 1, 2026, 9:19 PM EDT
Withdrawn No phase listed Observational

Inter-Observer Reliability and Accuracy of Tricuspid Annular Plane Systolic Excursion in Patients With Suspected PE in the ED

NCT02356120
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Echocardiogram
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 1, 2026, 9:19 PM EDT
Withdrawn Phase 2 Interventional

Effect of iNO in Patients With Submassive and Massive PE

NCT04996667
View directory record Official record
Conditions
Pulmonary Embolism, Pulmonary Embolism Subacute Massive
Interventions
inhaled nitric oxide (iNO)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 1, 2026, 9:19 PM EDT
Completed No phase listed Observational

Assessing the Prognosis of Pulmonary Embolism Using Clinical and Imaging Biomarkers (Retrospective & Prospective )

NCT00805246
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
2
States / cities
St Louis, Missouri • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Sep 1, 2026, 9:19 PM EDT
Recruiting Not applicable Interventional

The PERSEVERE Study

NCT06588634
View directory record Official record
Conditions
Pulmonary Embolism, Pulmonary Thromboembolism
Interventions
FlowTriever System, Standard of Care
Device · Procedure
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
15
States / cities
New Haven, Connecticut • Orlando, Florida • Sarasota, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 1, 2026, 9:19 PM EDT